Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynette Keyes-Elstein

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Diabetologia|April 8, 2016
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trialStephen E Gitelman, Peter A Gottlieb, Eric I Felner, et al.
Annals of the Rheumatic Diseases|November 10, 2018
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohortsElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2020
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisChiara Bellocchi, Jun Ying, Ellen A Goldmuntz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus ErythematosusCynthia Aranow, Diane L Kamen, Maria Dall'Era, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trialStephen E Gitelman, Peter A Gottlieb, Mark R Rigby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 1, 2018
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled TrialE William St Clair, Alan N Baer, Chungwen Wei, et al.
American Journal of Respiratory and Critical Care Medicine|March 2, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled TrialRoham T Zamanian, David Badesch, Lorinda Chung, et al.
Arthritis Care & Research|September 17, 2021
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal DataLynette Keyes-Elstein, Ashley Pinckney, Ellen Goldmuntz, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Rheumatology (Oxford, England)|October 20, 2019
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritisCynthia Aranow, John Cush, Marcy B Bolster, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Diabetologia|April 8, 2016
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trialStephen E Gitelman, Peter A Gottlieb, Eric I Felner, et al.
Annals of the Rheumatic Diseases|November 10, 2018
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohortsElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2020
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisChiara Bellocchi, Jun Ying, Ellen A Goldmuntz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus ErythematosusCynthia Aranow, Diane L Kamen, Maria Dall'Era, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trialStephen E Gitelman, Peter A Gottlieb, Mark R Rigby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 1, 2018
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled TrialE William St Clair, Alan N Baer, Chungwen Wei, et al.
American Journal of Respiratory and Critical Care Medicine|March 2, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled TrialRoham T Zamanian, David Badesch, Lorinda Chung, et al.
Arthritis Care & Research|September 17, 2021
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal DataLynette Keyes-Elstein, Ashley Pinckney, Ellen Goldmuntz, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Rheumatology (Oxford, England)|October 20, 2019
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritisCynthia Aranow, John Cush, Marcy B Bolster, et al.
Pageof 3